| Abstract | Alzheimer's Disease (AD), the most common form of Dementia, is a brain disorder that affects memory, cognition, and behavior. It currently affects 6.7 million Americans in the United States and interferes with daily life. Neuroinflammation in the brain is thought to worsen symptoms and drive the progression of the disease. Inflammation is mediated by the transcription factor NF-kB, which typically leads to transcription of pro-inflammatory cytokines, including TNF-a and IL-1B. The transcription of these cytokines can lead to a cycle of chronic inflammation if left unregulated. In collaboration with P2D Biosciences and Dr. Kayla Green's Lab, we focused on testing compounds for their ability to reduce inflammation. Some of the compounds tested here have been shown to reduce cognitive defects in a mouse model of AD. In this study we are trying to understand the mechanism of action of these drugs. We are looking at the effect on the transcription factor NF-kB. |
